Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 93Carcinoma, Non-Small-Cell Lung 46Neoplasms 33Carcinoma, Renal Cell 24Neoplasm Metastasis 16Colorectal Neoplasms 13Carcinoma, Hepatocellular 12Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Lung Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Advanced Cancer 9Squamous Cell Carcinoma of Head and Neck 8Uveal Melanoma 7Stomach Neoplasms 7Skin Neoplasms 7Mesothelioma 7Kidney Neoplasms 7Carcinoma, Transitional Cell 7Recurrence 6Pancreatic Neoplasms 6Liver Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Solid Tumor 4

Interventions

sitravatinib 1pembrolizumab 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced or Metastatic Solid Malignancies × Ipilimumab × Clear all
NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Mirati Therapeutics Inc.

Phase 2/3 Completed
52 enrolled

Advanced or Metastatic Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡